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Summary 
Effectiveness and side-effect profile data on pharmacotherapy for daytime sleepiness 
in central hypersomnias are largely based upon randomised controlled trials. Evidence 
regarding the use of combination therapy is scant. The aim of this study was to 
examine the effectiveness and occurrence of drug-related side-effects of these drugs 
in routine clinical practice. Adult patients diagnosed with a central hypersomnia over 
a 54-month period at a tertiary sleep disorders centre were identified retrospectively. 
Side-effects were recorded at every follow-up visit. 126 patients, with a total of 3,275 
patient-months of drug exposure, were categorised into narcolepsy type 1 (n=70), 
narcolepsy type 2 (n=47) and idiopathic hypersomnia (n=9). Modafinil was the most 
common drug used as a first-line treatment (93%) and in combination therapy (70%).  
39% of the patients demonstrated a complete, 25% partial and 36% a poor response to 
treatment. Combination treatment improved daytime sleepiness in 55% of the patients 
with residual symptoms despite monotherapy. 60% of patients reported side-effects, 
and 30% reported treatment-limiting side-effects. Drugs had similar side-effect 
incidence (p=0.363) and their side-effect profile met those reported in the literature. 
27% of the patients received combination treatment and had fewer side-effects 
compared to monotherapy (29.4% versus 60% respectively, p=0.001). Monotherapy 
appears to achieve satisfactory symptom control in most patients with central 
hypersomnia, but significant side-effects are common. Combination therapy appears 
to be a useful and safe option in patients with refractory symptoms.  
Keywords: pharmacotherapy, therapeutic schemes, treatment outcome, NT1, NT2, 
IH 
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Introduction 
The principal central hypersomnias are narcolepsy, affecting approximately one in 
every 3000 people (Longstreth et al., 2007), and idiopathic hypersomnia (IH), which 
is encountered approximately ten times less frequently than narcolepsy in sleep centre 
cohorts (Billiard and Dauvilliers, 2001).  
The current mainstay treatments for daytime sleepiness in central hypersomnias are 
the wake promoter modafinil, stimulant therapy, and sodium oxybate, the sodium salt 
of gamma-hydroxybutyrate (GHB). Although lifestyle changes such as addressing 
problems with sleep hygiene and taking scheduled naps have been shown to be of 
some benefit, pharmacotherapy is required to overcome hypersomnolence in most 
cases (Billiard et al., 2006; Morgenthaler et al., 2007).  
The current first-line drug of choice in patients with narcolepsy is modafinil (Billiard 
et al., 2006; Morgenthaler et al., 2007) supported by the results of well-designed, 
randomized trials (Moldofsky et al., 2000; Schwartz et al., 2004; Schwartz et al., 
2003; Schwartz et al., 2005; Ivanenko et al., 2003; Black and Houghton, 2006; Saletu 
et al., 2004). In IH, while evidence is significantly more limited, modafinil is still 
considered the first line option (Bastuji and Jouvet, 1988; Morgenthaler et al., 2007; 
Philip et al., 2014; Mayer et al., 2015). Modafinil is a non-amphetamine wake-
promoting agent, thought to act through dopaminergic, adrenergic, serotonergic, and 
gamma-aminobutyric acid pathways, although its exact mechanism of action is 
unknown. Major reported side effects (SEs) include headache, nausea, rash, dry 
mouth, anxiety and anorexia (Littner et al., 2001; Billiard et al., 2006; Broughton et 
al., 1997; U.S.M.N.M.S.G., 1998; U.S.M.N.M.S.G., 2000).   
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Due to lack of evidence on benefit-to-risk ratios from existing studies, amphetamines 
and methylphenidate are considered second line treatments for narcolepsy and IH 
(Billiard et al., 2006; Morgenthaler et al., 2007), except in paediatric populations, 
where methylphenidate is used as a first-line treatment due to concerns regarding 
hypersensitivity reactions with modafinil. Major SEs of these agents include 
palpitations, tachycardia, hypertension, insomnia, diarrhoea, constipation, anorexia 
and infrequently psychotic episodes. In comparison to amphetamines, 
methylphenidate is less frequently associated with loss of appetite and increased 
blood pressure but it is equally associated with insomnia, tachycardia, headache, 
dizziness and nervousness (Mitler et al., 1994; Littner et al., 2001; Guilleminault et 
al., 1974). Scant data exist examining the utility and safety of these drugs used in 
combination. 
Sodium oxybate is currently authorized by the European Medicines Agency to treat 
narcolepsy with cataplexy in adults, and by the US Food and Drug Administration 
(FDA) to treat cataplexy in patients with narcolepsy, with an “expanded indication” 
for the treatment of excessive daytime sleepiness (EDS)(Billiard et al., 2006; 
Morgenthaler et al., 2007) . In routine European clinical practice, and particularly in 
the UK, sodium oxybate is reserved for a sub-group of patients with narcolepsy with 
cataplexy, patients more likely to be on multiple other therapies with a more severe 
phenotype (Drakatos et al.). Enuresis, nausea, dizziness and headache may commonly 
develop while on sodium oxybate treatment, especially on higher doses, while 
dizziness and gait problems may be experienced if patient wakes while the drug is 
still effective (X.I.S.G., 2002; X.I.S.G., 2003; X.I.S.G., 2004; X.I.S.G., 2005; 
Mamelak et al., 2015; European et al., 2011). The abuse potential of the drug is an 
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additional concern (Billiard et al., 2006). None of the aforementioned drugs are 
considered safe for administration during pregnancy (Littner et al., 2001). 
Except for a retrospective study comparing the efficacy of sodium oxybate and 
modafinil in patients with narcolepsy and cataplexy, no direct comparison data exist 
with the traditional stimulants, and the latter tend to be reserved for those patients 
who do not benefit from or are unable to tolerate modafinil (Black et al., 2016; 
Billiard et al., 2006; Morgenthaler et al., 2007).  
The primary aim of this study was to provide a snapshot into current clinical practice 
and estimate the extent and distribution of drug-related side effects in patients with 
narcolepsy and IH. Effectiveness of the drugs as monotherapy or combination 
treatment is discussed. 
Methods 
Patient selection 
Drug-naive patients with a diagnosis of narcolepsy or IH were identified 
retrospectively from the medical records, on the basis of nocturnal polysomnography 
(NPSG) followed by multiple sleep latency test (MSLT), in combination with the 
clinical presentation at a tertiary referral sleep disorders centre between June 2009 
and November 2013. All patients had been evaluated by a sleep physician and had 
completed a sleep diary and/or two weeks of actigraphy prior to their sleep studies. A 
standardised pharmacological approach was shared between clinicians, with modafinil 
offered as first option followed by methylphenidate, amphetamines and sodium 
oxybate. The criteria to add another drug to monotherapy or combined therapy based 
on the above pharmacological approach, was if partial response was observed and no 
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intolerable SEs have occurred.  Methylphenidate was not combined with 
amphetamines. Approval for this study was obtained from Guy's and St Thomas' 
Hospital review board on human research (project number 4262).  
The NSPG and MSLT assessment was performed as per current recommendations 
(Berry R. et al., 2012.; Littner et al., 2005). 
Cases were subsequently reviewed and diagnoses of narcolepsy type 1 (NT1), 
narcolepsy type 2 (NT2), and IH were made according to the International 
Classification of Sleep Disorders, 3rd edition (ICSD-3) criteria (A.A.S.M., 2014.). 
Patients with diagnostic uncertainty, such as the presence of psychiatric disease, 
incomplete clinical information, less than 6 hours of sleep during the NPSG, technical 
issues, failure to stop sleep-interfering medications and lack of compliance with the 
treatment of other sleep disorders, were excluded. The presence of additional sleep 
disorders, such as periodic limb movement during sleep (PLMS) or sleep disordered 
breathing, was not automatically a basis for exclusion if patients were already treated 
or the conditions were deemed to have no clinical significance, e.g. where an NT1 
diagnosis was based on the presence of clear cataplexy coupled with pathognomonic 
sleep studies, or when repeated polysomnographic assessment did not confirm the 
previously seen increased number of periodic limb movements during sleep, but 
ICSD-3 criteria were fulfilled for NT2 diagnosis. Only patients with a follow-up (FU) 
period of at least six months were included. 
Data collection 
A full medical history, Epworth Sleepiness Scale (ESS) scores, sleep history, sleep 
study results and demographics were recorded for all patients. Treatment response 
regarding EDS and at the last FU, was assessed qualitatively by considering a three-
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group response categorisation, in line with two previously published studies (Drakatos 
et al., 2016; Ali et al., 2009).  These three categories consisted of: ‘complete 
response’, which correlated with adjectives such as ‘excellent’, ‘great’ or ‘entirely 
satisfactory’, provided there was no change in pharmacotherapy; ‘partial response’, 
which correlated with phrases such as ‘doing better’ or ‘improved’, but in the setting 
of increased dose adjustment of stimulant medication or adding another drug; and ‘no 
or poor response’, which associated with phrases such as ‘still sleepy’ or 
‘discontinued due to development of SEs’ and/or with a subsequent switch to another 
medication. In order to assess the validity of the outcome measurement scale, an inter-
rater agreement analysis was performed on scoring of two blinded independent raters 
(KP, PD) for 20 patients. The agreement was found to be high (Cronbach’s a = 
0.895)(Cronbach, 1951), and the residual disagreements between raters were 
discussed further on a patient by patient basis until consensus was reached. 
Safety and tolerability were evaluated based on the reported SEs, without a pre-
established list of SEs, during every FU visit per monotherapy and combined 
therapeutic regimes and per diagnosis group. Patients were informed of possible drug-
related SEs and were advised of gradual dose increases followed by monthly FUs 
until a stable dose had been achieved for each initiated drug, depending on treatment 
response and potential side effects.  Subsequently patients were followed up routinely 
on an annual basis unless a need occurred for an earlier appointment. Sleep-
specialised pharmacist emergency appointments were also offered to patients to assist 
with occurring SEs at any point and during dose escalation. SEs were categorized into 
groups: namely infections, psychiatric, neurological, gastrointestinal, general, sleep 
disorders and cardiological SEs in keeping with those listed in the summary of the 
products characteristics (XYREM.; Modafinil.; Methylphenidate.). Reports from 
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patients' notes of mood changes throughout the day, which could vary from elevated 
mood to anger to sadness within a few hours, and changes in mood clearly out of 
proportion to circumstances which could also cause impairment in functioning, were 
grouped under the term mood swings.  Psychotic symptoms were confirmed by 
formal psychiatric assessment and were made according to the Diagnostic and 
Statistical Manual of Mental Disorders 5th edition (DSM-V) criteria (A.P.A., 2013.).   
Patients exposed to sodium oxybate were limited due to restrictions that apply in UK 
and thus precluded valuable conclusions. To avoid selection bias these were included 
in the cohort and overall analysis, but drug-related analysis is limited to modafinil and 
stimulants.   
Statistical Analysis 
SPSS statistical analysis program (IBM, V20.0, Chicago, IL/US) was used for 
statistical analysis. Data is reported as mean ± standard deviation (SD), unless stated 
otherwise. The association of categorical variables was analysed using Fisher-
Freeman-Halton test and Chi-square test as appropriate. Following testing for 
normality, the similarity of the means for two groups was compared by using Mann-
Whitney U test, and for three groups the Kruskal–Wallis test with Dunn’s Multiple 
Comparison Test as and when needed. Ordinal regression analysis was applied to 
evaluate potential predictors of treatment outcome. A value of p<0.05 was considered 
as statistically significant. 
Results 
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Retrospective data collection over a four and a half-year period identified 251 
previously treatment naïve patients with an initial diagnosis of central hypersomnia. 
125 patients were finally excluded from the analysis as outlined in figure 1.  
Insertion of Fig. 1 
The 126 patients (37% male) were classified into NT1 (n = 70), NT2 (n = 47), and IH 
(n = 9). Hypocretin values were limited to 10 patients. 39 patients had been HLA 
typed for the genetic locus DQB1 *0602, of whom 13 were positive and diagnosed 
with NT1 and 26 negative and belonged in the NT2 group. One patient with IH 
exhibited a mean sleep latency of >8min and the final diagnosis was based on an 
increased 24-hour sleep time combined with the presence of clinical manifestations 
associated with IH, such as morning sleep drunkenness and unrefreshing long daily 
naps.  
There were no significant differences in the age, gender distribution or body mass 
index between the diagnostic categories. However, the NT1 group was subjectively 
sleepier, as measured by the ESS, than the NT2 (p = 0.021) and both NT1 and NT2 
groups were objectively sleepier compared to IH group based on the mean sleep 
latency (MSL) (p=0.001 and p=0.024 respectively). With regard to sleep architecture, 
the NT1 group had significantly lower sleep efficiency (p=0.002) with higher 
percentage of sleep stage 1 (N1) when compared to the NT2 group, (p = 0.001). 
(Table 1) 
Insertion of Table 1. 
 
Effectiveness 
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The FU time for our cohort had a median 25.4 months (interquartile range 12.8-38.2), 
with a total of 3,275 patient-months of drug exposure. At last FU, 49 (39%) patients 
demonstrated a complete response to treatment, 32 (25%) partial and 45 (36%) a poor 
response to treatment. The change in ESS (ESS) between these response groups was 
statistically significant (Table 2). 
 
Insertion of Table 2. 
The mean daily doses of prescribed monotherapy at the last FU are shown in table 3. 
Modafinil, as per current recommendations, was the most common first-line treatment 
used in our cohort (93%) (Billiard et al., 2006; Morgenthaler et al., 2007). Of those, 
63% remained on the drug and 80% of these were receiving it as a monotherapy at 
their last FU. Methylphenidate was the next most commonly prescribed drug (39%) 
for our patients and, as with modafinil, the majority of those (59%) remained on the 
drug at their last FU.  Only 20% of the patients received amphetamines and 14% 
sodium oxybate, with the majority remaining on these drugs on their last FU (92% 
and 67% respectively). Comparison of treatment responses between monotherapies, 
excluding sodium oxybate, did not reveal any significant difference (p=0.109). (Table 
3)  
Insertion of Table 3.  
 92 (73%) of our patients were on monotherapy and 34 (27%) on a combination 
treatment at their last FU. The two groups did not differ significantly in age, BMI, 
gender and diagnoses (p>0.05). Comparison of treatment outcome between 
monotherapy and combination treatment at last FU showed better symptom control in 
patients receiving monotherapy (p=0.009). (Table 2) Combination therapy was 
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offered to patients that had a partial response to monotherapy and a transition to 
complete response was seen in 17.6% of these cases. Another 38.2% reported 
improvement in EDS compared to monotherapy but did not fulfill the criteria to enter 
the complete response group.  Treatment outcome could not be predicted by 
demographics, diagnoses or drug choice (p=0.276). Comorbidities and concomitant 
medication were not associated with treatment outcome (p=0.303 and p=0.0.439 
respectively), or with the number of drugs patients were receiving for EDS treatment 
at the last FU (p=0.913 and p=0.899 respectively).  
52.5% (37/70) of NT1 patients were receiving antidepressants as part of their 
cataplexy treatment, and there was no association with treatment outcome (p=0.276), 
or with the number of medications required for EDS treatment at last FU (p=0.054).  
 
 
Safety 
Almost 2/3 of patients (76/126) reported drug-related SEs when receiving 
monotherapy. As a proportion of those exposed to the respective monotherapy, (47%) 
of patients on modafinil reported SEs followed by methylphenidate (37%), and 
amphetamines (31%) (p=0.363). Patients that experienced SEs while on any 
monotherapy were marginally younger compared to those that did not (35.5±12.6 
versus 40.0±13.1, p=0.048) and did not differ significantly in BMI (p=0.225), gender 
distribution (p=0.171) and drug doses (p>0.05, table 4). SEs incidence was not dose-
dependent for modafinil, methylphenidate and amphetamines (p=0.559, p=0.511 and 
p=0.702 respectively) nor associated with the ESS as recorded in the first 
appointment, or the diagnoses (p=0.587 and p=0.121 respectively). (Fig. 2)..  A weak 
inverse association between age and SEs was found (r=-0.177, p=0.048). Further 
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analysis showed that comorbidities and concomitant medications were not associated 
with SEs incidence (p=0.569 and p=0.310 respectively) nor with antidepressants 
prescribed for cataplexy in NT1 patients (p=0.632).  
Insertion of Fig. 2. 
Headache (15.2%), mood swings (10.7%) and palpitations (8.9%) were the most 
commonly reported SEs from patients receiving modafinil. Patients on 
methylphenidate were primarily affected by induced anxiety (15%) and mood swings 
(12.5%), and patients on amphetamines by dyspepsia (12.5%) and headache (12.5%). 
(Table 4) 
Insertion of Table 4. 
30% of our patients experienced SEs that failed to resolve, or were severe or 
intolerable while receiving monotherapy, leading to a change of their medication. 
Based on our experience, the timing of the drug discontinuation was primarily 
affected by patient's subjective experience of SE intensity along with the severity of 
the SE, namely palpitations and psychosis. Almost one third of the patients receiving 
modafinil or amphetamines had to discontinue the drug, as did 20% of patients that 
received methylphenidate. When the above discontinuation rates are expressed as a 
proportion of those that experienced SE for each drug, then all patients on 
amphetamines had finally to stop the drug, while the respective percentages for 
modafinil and methylphenidate were 70% and 53%.  The use of modafinil was most 
commonly ceased due to headache (21%), mood swings (15%) and cardiovascular 
incidents (12.5%), including palpitations and hypertension; methylphenidate most 
commonly caused dizziness/disorientation (37.5%) and mood swings (37.5%); 
amphetamines were primarily discontinued due to gastrointestinal (GI) problems such 
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as nausea and dyspepsia (40% of the reported causes). One incident of psychosis and 
one of suicidal ideation were reported in patients on dexamphetamine and modafinil 
respectively, none of whom had a previous relevant psychiatric history. Importantly, 
these symptoms resolved after discontinuation of the responsible drug in both 
patients. 
Patients reporting intolerable SEs were compared with patients with no SEs, and those 
that experienced mild or resolving SEs. The former group consisted of younger 
patients compared to those with no SEs (33.86±12.56 versus 40.04±12.89 years, 
p=0.006), but did not reach the level of significance against those with mild or 
resolving SEs (33.86±12.57 versus 39.94±12.05, p=0.055).  BMI and gender 
distribution did not differ significantly between groups (p=0.591 and p=0.376 
respectively). Drug doses for modafinil, methylphenidate and amphetamines also did 
not differ significantly between groups (p=0.194, p=0.513 and p=0.186 respectively) 
and no dose-dependent effect was found for the occurrence of intolerable SEs in the 
cohort (p=0.764, p=0.649 and p=0.299 respectively). Age was inversely correlated 
with the presence of intolerable SEs (r=-0.245, p=0.006).  
With regard to combination therapy, 27% (34/126) of our patients were exposed and 
10 (29.4%) of those reported SEs, which led to treatment discontinuation in 8/34 
(23.5%) of the patients. The most commonly combined therapeutics were 
modafinil/methylphenidate (35%), modafinil/amphetamines (23.5%) and 
methylphenidate/sodium oxybate (17.6%), with similar treatment outcome and SEs 
incidence (p=0.320 and p=0.111 respectively). 70% of the combination therapies 
included modafinil and accounted for 79% of the complete and partial response seen 
in patients receiving combination therapy. The majority of the patients exposed to 
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combination therapy were diagnosed with NT1 (82%). Combined treatment was 
associated with lower SEs incidence compared to monotherapy (29.4% versus 60% 
respectively, p=0.001) 
Discussion 
In this study, we analysed drug-related SEs and effectiveness in clinical practice 
following current recommendations on EDS treatment approach in hypersomnias of 
central origin. The exposure to monotherapy was associated with frequently reported 
SEs and a high discontinuation rate. Recorded SEs were consistent with previously 
reported profiles for the specific drugs. Patients that were exposed to combination 
therapy (27%), reported a lower incidence of SEs (29.4%, p=0.001). Combination 
therapy improved EDS in 55% of the patients previously receiving monotherapy, and 
offered a complete or partial resolution of symptoms in a quarter of our cohort. These 
findings should however be interpreted through the prism of clinical practice 
standards and guidelines application rather than as a direct comparison of drug safety 
and effectiveness.  
In this study, current recommendations on pharmacotherapy were followed but were 
influenced by the restrictions on sodium oxybate administration that apply in UK, 
with the majority of the patients being initiated on modafinil (93%), leaving the 
traditional stimulants as a second line treatment when modafinil usage was limited 
either by lack of effectiveness or limiting SEs. Nevertheless the recorded SEs meet 
the existing safety profiles for modafinil and stimulants (Littner et al., 2001; Billiard 
et al., 2006; Ali et al., 2009) and no dose-dependent association was found, as seen in 
the literature (Mitler et al., 2000). In our study there was a weak association of SEs 
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with younger age, in contrast with prior data from our group examining the use of 
sodium oxybate (Drakatos et al.).   
Interestingly, while insomnia is considered a significant side effect associated with 
wake promoters and stimulant usage, in our study insomnia very rarely led to drug 
discontinuation as sleep problems were usually resolved with better drug timing 
administration or/and improved sleep hygiene. Cardiovascular related SEs were 
primarily associated with modafinil administration, with fewer seen with 
methylphenidate use, and in contrast to the existing literature, none with 
amphetamines (Billiard et al., 2006; Littner et al., 2001). Since SEs were not dose-
dependent, a possible explanation could be that the worse safety profile of 
amphetamines might have led to a more cautious approach with regard to dose 
escalation as evidenced from table 3 compared to modafinil. Furthermore, 
amphetamines, due to their rapid boost effect on alertness and the awareness of its 
worse safety profile, may be more commonly used by patients on an as needed basis 
rather than on a regular basis. In our study the standard approach and 
recommendation for each drug administered was to be used on a regular basis. It has 
been noticed though, that patients could at times and depending on their personal 
preference, daily commitments, sensitivity to drugs and ability to cope with 
sleepiness, take drugs on as needed basis for a few days a month which may have 
impacted our results. 
In line with existing data, mood swings, nervousness, anxiety and emotional lability 
were common causes of drug discontinuation (Littner et al., 2001; Billiard et al., 
2006). Despite the close monitoring of the patients at the initiation of each drug and 
until stable dose had been achieved, drug discontinuation due to SEs remained an 
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individual decision. This means that in cases where the drug was stopped after only a 
few doses, not enough time would have passed to possibly let SEs to diminish or 
resolve, and will potentially have affected our results. Only 14% of our patients were 
exposed to sodium oxybate, reflecting the licensing and financial restrictions that 
apply in the UK, limiting the evaluation capacity of its safety profile.  
As mentioned above, there is little published evidence examining the safety of 
combination therapy in this area (Black et al., 2016). 27% of our patients were 
exposed to combinations of drugs. The SE rate of combination therapy compared to 
monotherapy appears to be lower (p=0.001). These data contradict with those reported 
by Black et al. where 23 patients with unknown response to stable doses of modafinil 
received sodium oxybate starting at 6g/night for four weeks and then 9g/night for the 
second four week period. This study reported a marginally higher incidence of SEs 
rate compared to monotherapy and placebo (p=0.040) (Black et al., 2016). In our 
study 34 patients received combination therapy after partial response to monotherapy 
was seen, and our data for that specific combination of drugs, i.e. modafinil and 
sodium oxybate, is limited to 6 patients, who had sodium oxybate gradually up 
titrated starting from 4.5g/night. Thus direct comparison of the two studies is 
problematic. Our results once again reflect prescribing practices, since this cohort 
would not include patients vulnerable to intolerable SEs on monotherapy in the first 
instance. Nevertheless, these data do lend support to the use of combination therapy 
of modafinil plus another drug as a reasonable strategy in routine clinical practice.  
Effectiveness data need to be interpreted with caution. At first glance these data imply 
that modafinil is more effective than other therapies, but once again, due to 
prescribing practices, this likely illustrates that patients refractory to treatment with 
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wake promoters may still benefit from stimulant medication. Thus, it does support the 
current strategy of escalating pharmacotherapy if there is little or no response to 
modafinil, suggesting that methylphenidate, amphetamines and sodium oxybate 
provide additional benefit above and beyond modafinil in the treatment of EDS 
(Billiard, 2008; Black and Houghton, 2006). Furthermore, combination of these drugs 
when a partial response to monotherapy is seen is also supported by our data. While 
monotherapy was found to be more effective compared to combination therapy, this 
likely reflects that the combination therapy was reserved for patients with EDS 
refractory to monotherapy. In 55% of these patients combination therapy offered a 
complete or improved partial response which combined with the lower SE incidence 
for combination therapy, clinically justified the continuation of the drugs.  
    
Limitations 
Due to the retrospective nature of the study, we were unable to comment on the 
compliance of patients to their pharmacotherapy which could alter the frequency of 
SEs experienced. Our findings reflect on 50% of the actual clinical cohort, due to 
strict exclusion criteria detailed in Figure 1, and also cannot reflect reliably on 
patients with IH due to their small number. Similar limitation applies to conclusions 
for amphetamines safety and effectiveness, and to a lesser extent to sodium oxybate. 
Furthermore, the use of the ESS and the three-response categorisation assessment rely 
on subjective rather than objective assessment of EDS.  The retrospective nature of 
the study has also resulted in the incomplete capture of ESS scores, as seen in table 2. 
Nonetheless our results support previous studies (Ali et al., 2009; Drakatos et al., 
2016). While drawing this sample from a single institution signifies the utilisation of a 
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consistent approach in data collection, a pre-established side effects list would have 
offered a more standardised assessment.  
Clinical practice in the management of hypersomnias of central origin is not expected 
to be universal. There remain discrepancies between European Medicines Agency 
(EMA) and US Food and Drug Administration (FDA) drugs licensing. In addition to 
the extended indication of sodium oxybate for EDS in US compared to Europe, 
armodafinil has also received approval for narcolepsy in US but not in Europe, while 
pitolisant was recently approved in Europe only. As previously discussed, country-
specific policies also apply as with sodium oxybate in UK and mazindol which is only 
easily available in France (Thorpy and Dauvilliers, 2015). This study provides 
potentially valuable information based on daily clinical experience in a UK based 
tertiary sleep centre, and prospective multi-centre international studies would be 
required to add credence to our findings and explore treatment in a holistic approach.  
Antidepressants have not received approval for NT1, either from the EMA and FDA, 
and are used as off label. In this study we focused on EDS control and safety profile 
of the drugs, irrespective of cataplexy control.  
Conclusion 
Following current recommendations on pharmacotherapy and based on clinical 
practice, monotherapy is a relatively safe and effective option for patients with central 
hypersomnia and combination therapy should be considered as an alternative in 
patients with refractory daytime sleepiness.   
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Fig 1. Flow chart of the patients included in the analysis. 
ICSD-3, International Classification of Sleep Disorders 3d edition 27; #, 21 patients with less than 6 
hours of sleep time on the nocturnal polysomnography; 17 NT2 patients who had less than 2 sleep-
onset REM periods on repeated polysomnographic assessments; 10 IH patients with a total 24-hour 
sleep shorter than 660 minutes and sleep efficiency significantly less than 90%*, psychiatric disorders; 
NT1, narcolepsy type 1; NT2, narcolepsy type 2; IH, idiopathic hypersomnia. 
 
Fig 2. Proportion of patients on each monotherapy that experienced any side effect 
and per diagnosis. 
 
NT1: narcolepsy type 1, NT2: narcolepsy type 2, IH: idiopathic hypersomnia; N/A, not applicable. 
Amphetamines were not prescribed in patients with IH. 
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